2023 API ɗin 88th CINA

Bayani game da JYMed a 2023 API CHINA

【a kan site】

Karkashin jagorancin mataimakin Janar Zhi Qin, Shenzhen JYMed Technology Co., Ltd. (nan gaba ana kiranta da JYMed) sun halarci wannan babban nunin. JYMed ya nuna samfurori masu fa'ida Semaglutide, Liraglutide, Tirzepatide, Oxytocin, Copper Peptide da Acetylhexapeptide-8 da sauransu ga abokan cinikin da ke ziyartar rumfar. Ma'aikatan tallace-tallace suna bayyana wa abokan ciniki daga nau'i-nau'i masu yawa kamar samfurori da tsarin masana'antu. Bayan samun zurfin fahimtar JYMed da peptide albarkatun kasa, abokan ciniki da yawa sun bayyana niyyarsu don yin aiki tare, suna sa ran ƙarin musayar da kuma neman yin aiki tare don ƙirƙirar sabon yanayin nasara don haɗin gwiwa.

【Jago a fasahar peptide da masana'antu】

Shenzhen JYMed Technology Co., Ltd. an kafa shi a cikin 2009, sadaukar da kai ga bincike da haɓakawa, samarwa, da siyar da peptides da samfuran peptide masu alaƙa. JYMed yana da cibiyar R&D guda ɗaya da manyan sansanonin samarwa guda uku (layukan samar da peptide API 20 da layin samar da ƙira 4). Fasahar haɓakawa ta mataki-mataki na iya biyan buƙatun buƙatun buƙatun buƙatun daban-daban, daga matakin mg zuwa 50kg / tsari, kuma ya kafa layin kwazo na peptide cytotoxic (OEB4/OEB5) da layin allurar peptide. Yana daya daga cikin masana'antun da ke da mafi girman sikelin samar da albarkatun peptide da aka haɗa da sinadarai a cikin Sin.

Babban ƙungiyar R&D na JYMed yana da fiye da shekaru 20 na ƙwarewar peptide kuma ya wuce binciken FDA sau biyu. JYMed yana da cikakken kuma ingantaccen tsarin masana'antu na peptide, yana ba abokan ciniki cikakkiyar sabis na masana'antar peptide, gami da R&D, samarwa, rajista, da tallafin ka'idoji masu dacewa na peptide APIs, peptide na dabbobi, peptide na ƙwayoyin cuta, da peptide na kwaskwarima.

Ta hanyar samar da kayan albarkatun ƙasa masu inganci da tallafin fasaha na ƙwararru, muna ƙoƙarin ƙirƙirar ƙima don samfuran ku a kowane mataki kuma muna taimaka muku faɗaɗa sabbin damar kasuwanci a kasuwa.